Chemcrux Enterprises Limited, a prominent player in the bulk drug intermediates sector, has announced a series of significant corporate developments, including the resignation of its Chief Financial Officer (CFO).

CFO Resignation

Ramesh Kambariya, the company's CFO, has tendered his resignation, effective from the end of business hours on August 11, 2025. In his resignation letter, Kambariya cited his decision to pursue opportunities that offer better financial growth to meet personal goals. He expressed gratitude for the trust and support received during his tenure and committed to ensuring a smooth transition.

Financial Performance

The company's Board of Directors, in a meeting held on August 6, 2025, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. The consolidated revenue from operations for Q1 FY2025-26 stood at ₹1,650.35 crore, showing a modest increase from ₹1,572.16 crore in the corresponding quarter of the previous year.

Key Corporate Actions

Several other important decisions were taken during the board meeting:

1. Employee Stock Option Scheme: The board approved the Chemcrux Enterprises Employee Stock Option Scheme 2025 ("ESOP 2025"), granting 20,00,000 options at ₹10 each to eligible employees.

2. Increase in Authorized Share Capital: The company plans to increase its authorized share capital from ₹15 crore to ₹20 crore, subject to shareholder approval.

3. Continuation of Directors: The board recommended the continuation of terms for three key directors upon reaching certain age milestones:

   • Girishkumar Shah as Whole Time Director and Executive Chairman (upon turning 70)
   • Sanjay Marathe as Managing Director (upon turning 70)
   • Bhanubhai Patel as Independent Director (upon turning 75)

4. Appointment of Secretarial Auditor: M/s. KSPS & Co. LLP has been recommended for appointment as the company's Secretarial Auditor for a five-year term starting FY 2025-26.

5. Annual General Meeting: The 29th Annual General Meeting is scheduled for September 24, 2025, to be held via video conferencing.

These developments signify Chemcrux Enterprises' focus on corporate governance, employee retention, and strategic growth. The company's ability to navigate these changes, particularly the CFO transition, will be crucial for its continued success in the competitive bulk drug intermediates market.

Financial Highlights

The company's financial performance shows a year-on-year increase in revenue, but a decrease in profitability, which may be attributed to various market factors and operational challenges.

Chemcrux Enterprises Limited , a leading manufacturer of bulk drug intermediates, has announced several significant decisions following its board meeting held on August 6, 2025. The company's board approved unaudited financial results for the first quarter ended June 30, 2025, and made key governance decisions that will shape its future.

Financial Performance

For the quarter ended June 30, 2025, Chemcrux Enterprises reported:

Key Board Decisions

Director Continuations

The board recommended the continuation of terms for three key directors, subject to shareholder approval at the upcoming Annual General Meeting (AGM):

1. Mr. Girishkumar Shah as Executive Chairman upon reaching age 70
2. Mr. Sanjay Marathe as Managing Director upon reaching age 70
3. Mr. Bhanubhai Patel as Independent Director upon reaching age 75

Increase in Authorized Share Capital

The board approved an increase in the authorized share capital from Rs. 15 crore to Rs. 20 crore, divided into 2 crore equity shares of Rs. 10 each, subject to shareholder approval at the AGM.

Employee Stock Option Scheme

A new Employee Stock Option Scheme 2025 (ESOP 2025) was approved, granting 20 lakh options of Rs. 10 each to eligible employees.

Management Changes

Mr. Ramesh Kambariya, the Chief Financial Officer, has resigned effective August 11, 2025.

Other Announcements

• Appointment of M/s. KSPS & Co. LLP as Secretarial Auditor for five years from F.Y. 2025-26 to F.Y. 2029-30.
• The 29th Annual General Meeting is scheduled for September 24, 2025, at 11:00 A.M. through video conferencing.

These decisions demonstrate Chemcrux Enterprises' commitment to corporate governance, employee welfare, and strategic growth. The company's focus on retaining experienced leadership while also planning for future expansion through increased share capital and employee stock options indicates a balanced approach to sustainable growth in the competitive bulk drug intermediates sector.